share_log

DEF 14A: Definitive information statements

DEF 14A: Definitive information statements

DEF 14A：股東委託書決議
美股sec公告 ·  04/26 06:13
Moomoo AI 已提取核心訊息
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, announced the filing of its definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC) for its upcoming 2024 Annual Meeting of Stockholders. The meeting is scheduled to be held virtually on June 13, 2024, at 1:00 p.m. Pacific Time. The proxy statement outlines several key proposals, including the election of two Class III directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of an amendment to increase the authorized number of shares of common stock from 40,000,000 to 80,000,000. The company, which was incorporated as Locust Walk Acquisition Corp. and underwent a business combination to become eFFECTOR Therapeutics, Inc., is inviting stockholders to attend the meeting online and cast their votes on these matters. The proxy materials are available on the Internet as part of the company's efforts to reduce environmental impact and delivery costs.
eFFECTOR Therapeutics, Inc., a biopharmaceutical company, announced the filing of its definitive proxy statement (DEF 14A) with the U.S. Securities and Exchange Commission (SEC) for its upcoming 2024 Annual Meeting of Stockholders. The meeting is scheduled to be held virtually on June 13, 2024, at 1:00 p.m. Pacific Time. The proxy statement outlines several key proposals, including the election of two Class III directors, the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of an amendment to increase the authorized number of shares of common stock from 40,000,000 to 80,000,000. The company, which was incorporated as Locust Walk Acquisition Corp. and underwent a business combination to become eFFECTOR Therapeutics, Inc., is inviting stockholders to attend the meeting online and cast their votes on these matters. The proxy materials are available on the Internet as part of the company's efforts to reduce environmental impact and delivery costs.
生物製藥公司Effector Therapeutics, Inc. 宣佈已向美國證券交易委員會（SEC）提交即將舉行的2024年年度股東大會的最終委託書（DEF 14A）。該會議定於太平洋時間2024年6月13日下午 1:00 以虛擬方式舉行。委託書概述了幾項關鍵提案，包括選舉兩名三類董事，批准安永會計師事務所作爲截至2024年12月31日的財政年度的獨立註冊會計師事務所，以及批准將普通股授權數量從4000萬股增加到8000萬股的修正案。該公司註冊爲Locust Walk Acquisition Corp.，並進行了業務合併，成爲Effector Therapeutics, Inc.，該公司邀請股東參加在線會議並就這些問題進行投票。代理材料可在互聯網上獲得，這是該公司減少環境影響和交付成本的努力的一部分。
生物製藥公司Effector Therapeutics, Inc. 宣佈已向美國證券交易委員會（SEC）提交即將舉行的2024年年度股東大會的最終委託書（DEF 14A）。該會議定於太平洋時間2024年6月13日下午 1:00 以虛擬方式舉行。委託書概述了幾項關鍵提案，包括選舉兩名三類董事，批准安永會計師事務所作爲截至2024年12月31日的財政年度的獨立註冊會計師事務所，以及批准將普通股授權數量從4000萬股增加到8000萬股的修正案。該公司註冊爲Locust Walk Acquisition Corp.，並進行了業務合併，成爲Effector Therapeutics, Inc.，該公司邀請股東參加在線會議並就這些問題進行投票。代理材料可在互聯網上獲得，這是該公司減少環境影響和交付成本的努力的一部分。
有用
沒用

該公告為獨立文件：

獨立文件1

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息